NJ State Employees Deferred Compensation Plan’s Rigel Pharmaceuticals RIGL Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,000	Closed	-$567K	–	322
2025 Q3	$567K	Hold	20,000	–	–	0.06%	268
2025 Q2	$375K	Hold	20,000	–	–	0.04%	320
2025 Q1	$360K	Hold	20,000	–	–	0.05%	331
2024 Q4	$336K	Hold	20,000	–	–	0.04%	349
2024 Q3	$324K	Hold	20,000	–	–	0.04%	359
2024 Q2	$164K	Hold	20,000	–	–	0.02%	439
2024 Q1	$296K	Hold	20,000	–	–	0.04%	378
2023 Q4	$290K	Hold	20,000	–	–	0.04%	381
2023 Q3	$216K	Hold	20,000	–	–	0.03%	414
2023 Q2	$258K	Hold	20,000	–	–	0.04%	401
2023 Q1	$264K	Hold	20,000	–	–	0.04%	395
2022 Q4	$300K	Hold	20,000	–	–	0.05%	362
2022 Q3	$236K	Hold	20,000	–	–	0.04%	393
2022 Q2	$226K	Hold	20,000	–	–	0.04%	407
2022 Q1	$598K	Hold	20,000	–	–	0.08%	254
2021 Q4	$530K	Hold	20,000	–	–	0.07%	286
2021 Q3	$726K	Hold	20,000	–	–	0.1%	218
2021 Q2	$868K	Hold	20,000	–	–	0.12%	195
2021 Q1	$684K	Hold	20,000	–	–	0.1%	226
2020 Q4	$700K	Hold	20,000	–	–	0.11%	194
2020 Q3	$480K	Hold	20,000	–	–	0.09%	227
2020 Q2	$366K	Hold	20,000	–	–	0.07%	279
2020 Q1	$312K	Hold	20,000	–	–	0.07%	275
2019 Q4	$428K	Hold	20,000	–	–	0.07%	308
2019 Q3	$374K	Hold	20,000	–	–	0.07%	325
2019 Q2	$522K	Hold	20,000	–	–	0.09%	240
2019 Q1	$514K	Hold	20,000	–	–	0.09%	263
2018 Q4	$460K	Buy	20,000 +2,000	+11%	+$56.4K	0.1%	245
2018 Q3	$578K	Buy	18,000 +7,000	+64%	+$210K	0.1%	259
2018 Q2	$311K	Sell	11,000 -4,000	-27%	-$142K	0.06%	422
2018 Q1	$531K	Hold	15,000	–	–	0.09%	292
2017 Q4	$582K	Sell	15,000 -14,000	-48%	-$533K	0.1%	300
2017 Q3	$737K	Sell	29,000 -6,500	-18%	-$158K	0.13%	234
2017 Q2	$969K	Hold	35,500	–	–	0.18%	180
2017 Q1	$1.18M	Hold	35,500	–	–	0.22%	157
2016 Q4	$845K	Hold	35,500	–	–	0.17%	206
2016 Q3	$1.3M	Buy	35,500 +10,000	+39%	+$287K	0.27%	121
2016 Q2	$569K	Hold	25,500	–	–	0.12%	254
2016 Q1	$645K	Hold	25,500	–	–	0.14%	235
2015 Q4	$773K	Hold	25,500	–	–	0.16%	216
2015 Q3	$630K	Buy	+25,500	New	+$761K	0.14%	239

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's RIGL Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 20,000 shares — an estimated $567K sold.

NJ State Employees Deferred Compensation Plan first reported a position in RIGL in Q3 2015 and held it in 41 quarters. The position peaked at $1.3M in Q3 2016. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 20,000 Rigel Pharmaceuticals shares in Q4 2025, an estimated $567K.
NJ State Employees Deferred Compensation Plan first reported a position in Rigel Pharmaceuticals in Q3 2015 and held it in 41 quarters.
NJ State Employees Deferred Compensation Plan's Rigel Pharmaceuticals position peaked at $1.3M in Q3 2016.
193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.